CN115584343A - Method for stem cell differentiation of caudal serotonin neurons, complete culture medium and application - Google Patents
Method for stem cell differentiation of caudal serotonin neurons, complete culture medium and application Download PDFInfo
- Publication number
- CN115584343A CN115584343A CN202211190987.9A CN202211190987A CN115584343A CN 115584343 A CN115584343 A CN 115584343A CN 202211190987 A CN202211190987 A CN 202211190987A CN 115584343 A CN115584343 A CN 115584343A
- Authority
- CN
- China
- Prior art keywords
- medium
- caudal
- culture medium
- stem cells
- dmh1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title claims abstract description 146
- 229940076279 serotonin Drugs 0.000 title claims abstract description 71
- 210000002569 neuron Anatomy 0.000 title claims abstract description 67
- 239000001963 growth medium Substances 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 20
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 16
- 230000024245 cell differentiation Effects 0.000 title claims description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 80
- 210000001202 rhombencephalon Anatomy 0.000 claims abstract description 34
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000002609 medium Substances 0.000 claims description 90
- 230000004069 differentiation Effects 0.000 claims description 43
- 230000006698 induction Effects 0.000 claims description 40
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 claims description 33
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 claims description 33
- 210000005036 nerve Anatomy 0.000 claims description 33
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 31
- 238000012258 culturing Methods 0.000 claims description 21
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 19
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims description 19
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 claims description 19
- 230000001079 digestive effect Effects 0.000 claims description 18
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 18
- 108010082117 matrigel Proteins 0.000 claims description 16
- 230000001537 neural effect Effects 0.000 claims description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 12
- 239000011148 porous material Substances 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000007877 drug screening Methods 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 230000004031 neuronal differentiation Effects 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 claims description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 3
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims description 3
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 238000011977 dual antiplatelet therapy Methods 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 239000002243 precursor Substances 0.000 abstract description 12
- 238000011160 research Methods 0.000 abstract description 5
- 210000001178 neural stem cell Anatomy 0.000 abstract description 4
- 238000012136 culture method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 239000002771 cell marker Substances 0.000 description 10
- 238000010166 immunofluorescence Methods 0.000 description 10
- 210000001671 embryonic stem cell Anatomy 0.000 description 9
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 description 8
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 8
- 102100027886 Homeobox protein Nkx-2.2 Human genes 0.000 description 8
- 101100460496 Homo sapiens NKX2-2 gene Proteins 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 210000000461 neuroepithelial cell Anatomy 0.000 description 7
- 230000029087 digestion Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 4
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 3
- 102100028404 Homeobox protein Hox-B4 Human genes 0.000 description 3
- 101000839788 Homo sapiens Homeobox protein Hox-B4 Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000001609 raphe nuclei Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000000862 serotonergic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- -1 trace elements) Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102000018918 Activin Receptors Human genes 0.000 description 2
- 108010052946 Activin Receptors Proteins 0.000 description 2
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000034972 Sudden Infant Death Diseases 0.000 description 2
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 210000003323 beak Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ZZXDRXVIRVJQBT-UHFFFAOYSA-N 2,3-dimethylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-N 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 101150017065 csn gene Proteins 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 101150090422 gsk-3 gene Proteins 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000002475 olfactory pathway Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000004001 thalamic nuclei Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a method for differentiating caudal serotonin neurons by stem cells, a complete set of culture medium and application, and particularly relates to a novel culture medium formed by adding a small molecular compound, so that human pluripotent stem cells are gradually induced to obtain hindbrain neural stem cells, ventral hindbrain caudal neural stem cells, serotonin precursor cells and hindbrain caudal serotonin neurons. The culture method is simple and convenient, can efficiently obtain mature serotonin neurons in a specific region, and provides an effective cell model for the research of related diseases of a serotonin system.
Description
Technical Field
The invention relates to the field of biological medicines, in particular to a method for differentiating caudal serotonin neurons by stem cells, a complete set of culture medium and application.
Background
Serotonin neurons are distributed in the posterior suture nucleus, and are capable of synthesizing and secreting serotonin neurotransmitters, regulating the respiratory rhythm, sleep patterns, mood, etc. in humans (Deneris, e.s. and s.c. wyler, sensorial transport networks and social interaction to mental health J. Nat Neurosci,2012.15 (4): p.519-27). Embryonic development studies in rodents have shown that serotonin neurons originate most ventrally in the hindbrain, distributed along the hindbrain. The two clusters are separated by r4, the r1 to r3 are beak clusters, and the r5 to r8 are tail clusters. In adult rodents, the rostral cluster of serotonin neurons is distributed in the dorsal and ventral raphe nuclei, with the serotonin neurons of the dorsal raphe nuclei originating from r1, projecting into the cortex, olfactory bulb and paraventricular thalamic nuclei. Serotonin neurons of the raphe nucleus originate mainly from r2 and r3, project to the olfactory bulb and hippocampus and the suprachiasmatic nucleus of the hypothalamus.
The serotonergic neurons of The tail cluster project down to areas such as The brainstem and spinal cord, and have functions such as thermoregulation and respiratory regulation (Deneris, e.and p. Gaspar, serotonin neuron depth: mapping molecular and structural identities [ J ]. Wiley interniscip Rev Biol, 2018.7), and sudden infant death syndrome is associated with abnormalities in The hindbrain caudal serotonergic system (Kinney, h.c., et al., the brazinten and Serotonin in The summer amino acid loss syndrome [ J ]. Annu Rev pathway, 2009.4 p.517-50.. However, the pathogenesis of the disease is not clear, and no corresponding cell model is available for studying the pathogenesis. The human pluripotent stem cells have the capacity of multidirectional differentiation, and specific neuron types can be obtained by in vitro induced differentiation. 2016 Lu et al, by precisely regulating WNT, SHH and FGF4 signaling pathways, first directed differentiation of human pluripotent stem cells into high purity serotonin neurons in the r2-r3 region on the rostral posterior brain beak side in vitro (Lu, J., et al, generation of serotonin neurons from human pluripotent cells [ J ]. Nat Biotechnol,2016.34 (1): p. 89-94.) was performed in vitro.
Valilahii et al obtained hindbrain-caudal serotonin neurons by adding high concentrations of RA and purmorphamine early in differentiation, but this method added high concentrations of purmorphamine early in differentiation, resulting in the presence of large numbers of Floor plate cells in the final differentiation system, affecting the purity of serotonin neurons (Valilahii P, vidyawan V, puspita L, et al. Generation of cad-type serotonin neurons and hindbrain-tissue oligonucleotides from hPSCs [ J ]. Stem Cell Reports, 2021.).
In conclusion, a key signal path for precisely regulating and controlling development is needed to directionally differentiate pluripotent stem cells into high-purity hindbrain caudal serotonin neurons in vitro, so that an effective cell model is provided for mechanism research and drug screening of diseases related to the hindbrain caudal serotonin system such as sudden infant death syndrome and the like.
Disclosure of Invention
The invention aims to establish a method for directionally differentiating human pluripotent stem cells into high-purity hindbrain caudal serotonin neurons, and provides a reliable cell model for mechanism and phenotype research of nervous system related diseases and drug screening.
To achieve the purpose, the invention provides the following technical scheme:
in a first aspect of the present invention, there is provided a method for differentiating caudal serotonin neurons from stem cells, comprising the steps of:
s1, culturing the pluripotent stem cells by using an E8 culture medium, wherein the fusion degree of the pluripotent stem cells reaches 60-80%, carrying out passage to a new culture plate according to 1:3, and continuously culturing by using E8;
s2, when the fusion degree of the pluripotent stem cells reaches about 80%, replacing the E8 with a first culture medium, and culturing for 6-8 days;
s3, digesting the cells by using trypLE cell digestive juice, carrying out passage to a Matrigel coated pore plate according to 1:5, replacing the cell digestive juice with a second culture medium the next day, and culturing for 6-8 days;
s4, digesting the cells by using trypLE cell digestive juice, carrying out passage to a Matrigel coated pore plate according to 1:3, replacing the cell digestive juice with a third culture medium on the next day, and culturing for 6-8 days;
s5, digesting the cells by using trypLE cell digestive juice and adding 1.5-4.5 x10 4 /cm 2 Subculturing on PO-Laminin coated glass slide, changing to fourth culture medium the next day, culturing for 3-4 days, changing to neuron differentiation culture medium, and continuously culturing for 2-4 weeks to obtain mature hindbrain caudal serotonin neurons;
wherein,
the first medium comprises: a nerve induction medium, SB431542, DMH1, CHIR99021;
the second medium comprises: a nerve induction medium, SB431542, DMH1, CHIR99021, purmorphamine, RA;
the third medium comprises: a nerve induction culture medium, SB431542, DMH1, CHIR99021, purmorphamine, RA and FGF4;
the fourth medium comprises: nerve induction medium, SB431542, DMH1, CHIR99021, RA and FGF4.
In the present invention, SB431542 is a small molecule inhibitor of activin receptor-like kinase (ALK);
in the present invention, DMH1 is a small molecule inhibitor of the bone morphogenetic protein receptor (BMP);
in the present invention, CHIR99021 is a small molecule inhibitor of glycogen synthase kinase 3 (GSK 3);
in the present invention, purmorphamine is a small molecule agonist of the Smo receptor;
in the present invention, RA means all-trans retinoic acid;
in the present invention, FGF4 refers to fibroblast growth factor 4.
Preferably, the neural induction medium includes DMEM/F12 medium, neurobasal medium, 1 xn 2,1 xb 27,1 xneaa, 1 xgutamax.
Preferably, the neuron differentiation medium includes Neurobasal medium, 1 xn 2,1 xb 27,1 xneaa, vitamin C, DAPT, GDNF, BDNF, TGF β 3, IGF1.
Preferably, the volume ratio of DMEM/F12 medium to Neurobasal medium in the nerve induction medium is 1:1.
Preferably, the molar concentration (μ M) ratio of purmophamine to RA in the second medium is: (0.4-1): (0.1-1).
Preferably, the molar concentration (μ M) ratio of purmophamine to RA in the third medium is: (1-2): (0.1-1).
Preferably, in the first culture medium, the molar concentration (μ M) ratio of SB431542, DMH1, CHIR99021 is 2: (1-3).
Preferably, the second medium comprises: the molar concentration (μ M) ratio of SB431542, DMH1, CHIR99021, purmorphamine, RA was 2:2: (1-3): (0.4-1): (0.1-1).
Preferably, the third medium comprises: the molar concentration (μ M) ratio of SB431542, DMH1, CHIR99021, purmorphamine, RA was 2:2: (1-3): (1-2): (0.1-1), the concentration of FGF4 is 10ng/ml.
Preferably, the fourth medium comprises: the molar concentration (μ M) ratio of the neural induction medium, SB431542, DMH1, CHIR99021, RA was 2:2: (1-3) (0.1-1), the concentration of FGF4 is 10ng/ml.
In a second aspect of the invention, a kit for differentiation of caudal serotonin neurons from stem cells is provided, which comprises a first medium, a second medium, a third medium and a fourth medium,
the first medium comprises: nerve induction medium, SB431542, DMH1, CHIR99021;
the second medium comprises: a nerve induction medium, SB431542, DMH1, CHIR99021, purmorphamine, RA;
the third medium comprises: a nerve induction culture medium, SB431542, DMH1, CHIR99021, purmorphamine, RA and FGF4;
the fourth medium comprises: a nerve induction culture medium, SB431542, DMH1, CHIR99021, RA and FGF4.
Preferably, the molar concentration (μ M) ratio of the purmophamine to the RA in the second medium is: (0.4-1): (0.1-1).
Preferably, the molar concentration (μ M) ratio of purmophamine to RA in the third medium is: (1-2): (0.1-1).
Preferably, the neural induction medium includes DMEM/F12 medium, neurobasal medium, 1 xn 2,1 xb 27,1 xneaa, 1 xgutamax.
Preferably, in the first culture medium, the molar concentration (μ M) ratio of SB431542, DMH1, CHIR99021 is 2: (1-3).
Preferably, the second medium comprises: the molar concentration (μ M) ratio of SB431542, DMH1, CHIR99021, purmorphamine, RA was 2:2: (1-3): (0.4-1): (0.1-1).
Preferably, the third medium comprises: the molar concentration (μ M) ratio of SB431542, DMH1, CHIR99021, purmorphamine, RA was 2:2: (1-3): (1-2): (0.1-1), the concentration of FGF4 is 10ng/ml.
Preferably, the fourth medium comprises: the molar concentration (μ M) ratio of the neural induction medium, SB431542, DMH1, CHIR99021, RA was 2:2: (1-3) (0.1-1), wherein the concentration of FGF4 is 10ng/ml.
In a third aspect, the invention provides an application of the caudal serotonin neuron prepared by the method provided by the invention in a cell model for in vitro mechanism research and drug screening of diseases related to the caudal serotonin system of the hindbrain.
Preferably, the method comprises the steps of:
s1, culturing the pluripotent stem cells by using an E8 culture medium, wherein the fusion degree of the pluripotent stem cells reaches 60-80%, carrying out passage to a new culture plate according to 1:3, and continuously culturing by using E8;
s2, when the fusion degree of the pluripotent stem cells reaches about 80%, replacing the E8 with a first culture medium, and culturing for 6-8 days;
s3, digesting the cells by using trypLE cell digestive juice, carrying out passage to a Matrigel coated pore plate according to 1:5, replacing the cell digestive juice with a second culture medium the next day, and culturing for 6-8 days;
s4, digesting the cells by using trypLE cell digestive juice, carrying out passage to a Matrigel coated pore plate according to 1:3, replacing the cell digestive juice with a third culture medium on the next day, and culturing for 6-8 days;
s5, digesting the cells by using trypLE cell digestive juice and adding 1.5-4.5 x10 4 /cm 2 Passage on PO-Laminin coated glass slide, changing to fourth culture medium the next day, culturing for 3-4 days, changing to neuron differentiation culture medium, and continuously culturing for 2-4 weeks to obtain mature hindbrain caudal serotonin neurons;
wherein,
the first medium comprises: nerve induction medium, SB431542, DMH1, CHIR99021;
the second medium comprises: a nerve induction medium, SB431542, DMH1, CHIR99021, purmorphamine, RA;
the third medium comprises: a nerve induction culture medium, SB431542, DMH1, CHIR99021, purmorphamine, RA and FGF4;
the fourth medium comprises: nerve induction medium, SB431542, DMH1, CHIR99021, RA and FGF4.
Compared with the prior art, the invention has the beneficial effects and remarkable progress that: the method for differentiating the caudal serotonin neurons by the stem cells, the complete culture medium and the application can be simple, convenient and efficient, can obtain a large amount of high-purity serotonin neurons with mature functions in a specific region, and provides an effective cell model for the mechanism research of related diseases and the evaluation and screening of drugs.
Drawings
To more clearly illustrate the technical solution of the present invention, the drawings required for the embodiment of the present invention will be briefly described below.
It should be apparent that the drawings in the following description are only drawings of some embodiments of the invention, and that other drawings can be obtained by those skilled in the art without inventive exercise, and the other drawings also belong to the drawings required by the embodiments of the invention.
FIG. 1 is a diagram showing the cell morphology of the human embryonic stem cell line H9 in an undifferentiated state, according to example 1 of the present invention;
FIG. 2 is a flow chart of the differentiation process of the directed differentiation of human pluripotent stem cells into retrocerebro caudal serotonin neurons according to example 2 of the present invention;
FIG. 3 is a morphological diagram of the various stages of the differentiation of the hindbrain caudal serotonin neurons in example 2 of the present invention;
FIG. 4 is a cellular immunofluorescence plot of markers for the early stage of hindbrain caudal serotonin neuron differentiation of example 3 of the present invention;
FIG. 5 is a cellular immunofluorescence map of a late differentiation marker of a hindbrain caudal neuron in accordance with example 3 of the present invention;
FIG. 6 is a cellular immunofluorescence plot of a hindbrain caudal serotonin neuron marker of example 3 of the present invention;
FIG. 7 is the sodium potassium current of the hindbrain caudal serotonin neurons of example 4 of the invention under voltage stimulation;
FIG. 8 shows the action potential and spontaneous action potential induced by the caudal-brain serotonin neurons of example 4 of the present invention under current stimulation;
FIG. 9 is a graph of secreted serotonin neurotransmitter levels of the hindbrain caudal serotonin neurons of example 5 of the present invention.
Detailed Description
In order to make the objects, technical solutions, beneficial effects and significant progress of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention.
It is to be understood that all of the described embodiments are only some, and not all, of the present invention; all other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It is to be understood that:
the term "differentiation" refers to the process by which cells of the same origin gradually develop populations of cells with different morphological, structural and functional characteristics, resulting in spatial differentiation of the cells, and temporal differentiation of the same cell from its previous state. The essence of cell differentiation is the selective expression of the genome in time and space, with the expression of different genes turned on or off, ultimately producing marker proteins.
The term "culture medium" refers to an artificially prepared nutrient for the growth and maintenance of microorganisms, plant tissues, and animal tissues, and generally contains carbohydrates, nitrogen-containing substances, inorganic salts (including trace elements), vitamins, water, and the like.
The specific meanings of the above terms in the present invention can be understood by those skilled in the art according to specific situations.
It should be further noted that the following embodiments may be combined with each other, and the same or similar concepts or processes may not be repeated in some embodiments.
The technical means of the present invention will be described in detail with reference to specific examples.
EXAMPLE 1 culture of human embryonic Stem cells
Use of E8 Medium (TeSR) TM -E8 TM ,Stem Cell technology, cat No. 05990) cultured human embryonic stem cell line H9 (WA 09, wiCell), cells were attached to Matrigel (Corning, cat No. 354277) coated six-well plates, cells were replaced with fresh medium every day, cultured for 4-6 days, and passaged with cell fusion of about 80%.
The specific steps of cell passage are as follows:
1. coating a pore plate with matrigel: according to the dilution ratio of the specification, the Matrigel is diluted to 4 ℃ precooled high-glucose DMEM (Gibco, cat No. 11995065), then added into a pore plate, incubated at 37 ℃ for 30 minutes, and sucked away before passage;
2. sucking off cell culture solution, adding DPBS (SIGMA) for washing, adding ReLeSR TM Cell digests (STEMCELL Technologies, cat # 05872) were aspirated within 1 minute and left at room temperature for 7 minutes;
3. after digestion, E8 resuspended cells were added
4. The cells were passaged as 1:3, seeded in six-well plates previously coated with matrigel, cultured using E8, and the cells were changed and observed for cell state every day, and the cell morphology is shown in fig. 1.
Example 2 directed differentiation of human embryonic Stem cells into caudate-caudal serotonin neurons
The steps of the directional differentiation of human embryonic stem cells into caudate-caudal serotonin neurons are shown in fig. 2, and the specific steps are as follows:
step 1, differentiation of human embryonic stem cells into retroencephalic neuroepithelial cells
When the confluency of the embryonic stem cells in example 1 reached about 80%, the cells were cultured for 6 to 8 days in a neural induction medium (first medium) containing compound component 1, and then subjected to digestion passaging using TrypLE digestive enzyme.
Wherein the basal medium of the nerve induction medium comprises DMEM/F12 (Gibco, cat # 11330-032), neurobasal medium (Gibco, cat # 21103049) (volume ratio 1:1), 1 xN 2 (Gibco, cat # 17502048), 1 xB 27 (Gibco, cat # 12587010), 1 xNEAA (Gibco, cat # 11140050), 1 xGlutaMax (Gibco, cat # 35050061). Compound component 1 comprises: 2 μ M SB431542, 2 μ M DMH1, 1.8 μ M CHIR99021 (small molecule compounds are all purchased from Chiozotan organisms).
The specific digestion steps are as follows:
1. coating a pore plate with matrigel: according to the dilution ratio of the specification, diluting the Matrigel to 4 ℃ precooled high-sugar DMEM, adding a pore plate, incubating at 37 ℃ for 30 minutes, and sucking away before passage;
2. performing nerve induction culture for 6-8 days, sucking culture solution, washing with DPBS, adding trypLE (Gibco, cat # 12604021) and washing, sucking digestive juice, placing cells in incubator, incubating at 37 deg.C for 4 min
3. Neural induction medium containing compound combination 1 was added and 10 μ M Y27632 (Tao Shu organism) was added, and after cell resuspension, the cells were passaged to matrigel coated well plates at a rate of 1:5.
Step 2, ventral and caudal organization of the hindbrain neuroepithelial cells
After obtaining the hindbrain neuroepithelial cells, namely the next day of passage in the step 1), the cells are replaced by a nerve induction medium (second medium) containing the compound component 2, cultured for 6 to 8 days, and digested and passaged by using TrypLE digestive enzyme.
Wherein the basic culture medium of the nerve induction culture medium contains DMEM/F12: neurobasal culture medium (the volume ratio is 1:1), 1 xN 2,1 xB 27,1 xNEAA and 1 xGlutaMax. Compound component 2 comprises: 2 μ M SB431542, 2 μ M DMH1, 1.8 μ M CHIR990210, 0.5 μ M purmorphamine, 100nM RA.
The specific digestion steps are as follows:
1. coating a pore plate with matrigel: according to the dilution ratio of the specification, diluting the Matrigel to 4 ℃ precooled high-sugar DMEM, adding a pore plate, incubating at 37 ℃ for 30 minutes, and sucking away before passage;
2. performing nerve induction culture for 6-8 days, sucking culture solution, washing with DPBS, moistening with TrypLE, sucking digestive juice, placing cells in incubator, incubating at 37 deg.C for 4 min
3. Neural induction medium containing compound combination 2 was added and 10 μ M Y27632 was added, after resuspending the cells, passaged to matrigel coated well plates at 1:3.
Step 3, differentiation of the hindbrain caudal serotonin neural precursor cells
After obtaining the neuroepithelial cells on the caudal ventral side of the hindbrain, i.e., the next day of the passage in step 2), the cells were replaced with a neural induction medium (third medium) containing compound component 3, cultured for 6 to 8 days, and subjected to digestion passage using TrypLE digestive enzyme.
Wherein the basic culture medium of the nerve induction culture medium contains DMEM/F12: neurobasal culture medium (the volume ratio is 1:1), 1 xN 2,1 xB 27,1 xNEAA and 1 xGlutaMax.
Compound component 3 comprises: 2 μ M SB431542, 2 μ M DMH1, 1.8 μ M CHIR990210, 2 μ M purmorphamine, 100nM RA, 10ng/ml FGF4 (PeproTech, cat # 100-31).
The specific digestion steps are as follows:
1. PO-Laminin coated slide: diluting polyornithine (PO, SIGMA) 200 times with sterile water, adding 50 μ L per slide with diameter of 12mm, coating at room temperature overnight, sucking PO off the next day, washing with sterile water twice, air drying, adding lamin (Thermo fisher, cat No. 23017015) diluted 50 times with DMEM/F12, coating at 37 deg.C for 3 hr, and sucking off before passage;
2. performing nerve induction culture for 6-8 days, sucking culture solution, washing with DPBS, moistening with TrypLE, sucking digestive juice, placing cells in incubator, incubating at 37 deg.C for 4 min
3. Adding the nerve induction culture medium containing the compound combination 3 and adding 10 mu M Y27632, after cell resuspension, 1.5-4.5 x10 of each slide with the diameter of 12mm 4 /cm 2 And (4) inoculating the cells.
4. Differentiation and maturation of hindbrain caudad serotonin neurons: the next day of passage in step 3), the culture was changed to a neural induction medium (fourth medium) containing compound component 4, and the culture was continued for 3 to 4 days, and then to a neuronal differentiation medium, and the culture was continued for 2 to 4 weeks.
Wherein the neuron differentiation medium comprises the following components: neurobasal medium, 1 XN 2,1 XB 27,1 XNEAA, 0.2mM vitamin C (sigma-Ardrich, cat # A4403), 2.5. Mu.M DAPT (Tao Shu organism, cat # T6202), 10ng/ml GDNF (PeproTech, cat # 450-10), 10ng/ml BDNF (PeproTech, cat # 450-02), 1ng/ml TGF beta 3 (PeproTech, cat # 100-36E), 10ng/ml IGF1 (PeproTech, cat # 100-11).
Compound 4 includes: 2 μ M SB431542, 2 μ M DMH1, 1-3 μ M CHIR99021, 0.1-1 μ M RA, 10ng/ml FGF4.
The morphological pattern of the various stages of differentiation of the caudal-cranial serotonin neurons of this example is shown in FIG. 3.
Example 3 identification of marker protein expression at various stages of differentiation by cellular immunofluorescence assay
The slides which were digested the next day of passaging in step 3 of the induction process of example 2 and cell slides which were cultured for 3 days and 2-3 weeks in step 4 were taken for cellular immunofluorescence identification, with the following specific steps:
3.1, sucking away the culture solution, adding DPBS (dimethyl-benzene-sulfonate) for washing once, and then adding 4% paraformaldehyde for fixing at room temperature for half an hour;
3.2, absorbing paraformaldehyde, and adding DPBS for washing for 3 times;
3.3, absorbing the DPBS and adding a sealing liquid, wherein the sealing liquid comprises the following components: DPBS containing 10% (v/v) donkey serum, 0.2% (v/v) Triton X-100 is incubated for half an hour at room temperature;
3.4 dilution of primary antibody with DPBS containing 5% (v/v) donkey serum and 0.2% (v/v) Triton X-100, for information see Table 1;
3.5, sucking off the confining liquid, adding the diluted primary antibody, and incubating overnight at 4 DEG C
3.6, removing primary antibody by suction, adding DPBS to wash for 3 times, 5 minutes each time
3.7 dilution of secondary antibody with DPBS containing 5% (v/v) donkey serum and DAPI
3.8, aspirate DPBS, add diluted secondary antibody and DAPI, incubate 45 minutes at room temperature in the dark
3.9, suck the secondary antibody, add DPBS to wash 3 times, each for 5 minutes
3.10 mounting using anti-quenching mounting agent
3.11 Observation and photography with a fluorescence microscope
The cellular immunofluorescence identification map is shown in fig. 4 and fig. 5. Fig. 4 is the hindbrain caudal neuronal precursor cell markers HOXB4, OLIG2, NKX2.2 for day 21 of differentiation, where HOXB4 is a postbrain caudal marker, NKX2.2 is a postbrain ventral neuronal precursor cell marker, and OLIG2 is a motor neuron marker. Figure 5 is a posterocaudal serotonin neuron precursor cell marker assay at day 24 of differentiation, in which HOXB4 is positive, NKX2.2 is positive, and OLIG2 is negative. FIG. 6 is a graph of markers 5-HT and Tuj1 at the neuronal differentiation stage cultured for 3 weeks, indicating that mature retrocerebro-caudal serotonin neurons were obtained.
TABLE 1 antibody information from cellular immunofluorescence experiments
Example 4 Whole cell patch Clamp assay for electrophysiological function of human embryonic stem cell differentiation-derived hindbrain caudal serotonin neurons
And filling the electrode solution after the electrode is drawn, wherein the resistance value is 6-8M omega. Before the electrode invades the liquid surface, a weak positive pressure is given to the interior of the electrode holder through a conduit connected with the electrode holder, and when the tip begins to contact the cell to prepare for forming a seal (seal), the conduit is opened by screwing and a constant negative pressure is applied through the conduit. After the sealing impedance reaches G omega level, the membrane potential is kept at-60 mV, and then the adherent cells are lifted to the lower part of the dosing tube of the rapid drug delivery perfusion system for the next experiment. Whole-cell electrode internal solution: 20mM KCl,10mM Na + -HEPES,121mM K + -gluconate,10mM BAPTA,4mM Mg 2+ ATP (adjusted pH =7.2, stored at 0 ℃). Whole-cell electrode external liquid: 127mM NaCl,1.9mM KCl,2.2mM CaCl 2 ,1.2mM KH 2 PO 4 , 26mM NaHCO 3 ,1.4mM MgSO 4 10mM glucose (pH = 7.3). The experiment control is carried out at the room temperature of 23-25 ℃, the filtering frequency is 1kHz, and the recording of the clamping voltage command and the current is controlled by clamp 10.3 (Molecular devices) software through a DigiData-1440A conversion interface.
Whole cell sodium potassium current recording
Under voltage clamping, a voltage of-40-30 mV was injected, and inward sodium and outward potassium currents were recorded under a 5mV one step stimulation, as shown in FIG. 7, indicating that the differentiating-derived serotonin neurons have mature sodium potassium channels.
Action potential recording
Under current clamp, the clamp current is 0pA, and the action potential is delivered under-40-100pA and 10pA one-step stimulation, as shown in FIG. 8, which shows that the serotonergic neuron from differentiation source has mature electrophysiological characteristics.
Example 5 detection of neurotransmitter secretion function of human embryonic Stem cell differentiation derived hindbrain caudal serotonin neurons by enzyme-linked immunosorbent assay
Cell culture fluid of the fifth week of the differentiation stage of the serotonin neurons and overnight incubation of non-serotonin neurons is collected, and the content of serotonin in the collected culture fluid is detected by using an enzyme linked immunosorbent assay kit (IBL, RE 59141). As shown in fig. 9, the extracellular serotonin content of non-serotonin neurons (NC, negative control) was Not detectable (Not deciteleble, n.d.), while the differentiation-derived serotonin (cSNs) content was significantly higher than the extracellular level of non-serotonin. Indicating that the differentiation-derived hindbrain caudal serotonin neurons have normal neurotransmitter synthesis and secretion functions.
Comparative example 1
1. Hindbrain neuroepithelial cells were obtained according to example 2, step 1;
2. example 2 in compound component 2 of step 2, on day 7 of differentiation, purmophamine and RA were added to promote posterocaudal and ventral differentiation, and we tried 0/0.25/0.5/1/2 μ M purmopamine to induce differentiation under 100nM RA for one week;
3. the cell immunofluorescence detects the proportion of ventral nerve precursor cell marker NKX2.2 and basal plate cell marker FOXA2 positive cells in cells differentiated for 14 days to total cells.
The results showed that the ratio of the ventral nerve precursor cell marker NKX2.2 in the 0.25. Mu.M puerhamine group was low, while the ratio of the basal plate cell marker FOXA2 in the 2. Mu.M puerhamine group was high, and the differentiation of the cells in the 0.5 and 1. Mu.M groups was the best.
Comparative example 2
1. Hindbrain neuroepithelial cells obtained according to step 1 of example 2
2. Hindbrain ventral neural stem cells obtained according to step 2 of example 2
3. Example 2 in compound fraction 3 of step 3, purmophamine was added on day 14 of differentiation, RA and FGF4 further promoted serotonin precursor differentiation, and we tried 0.5/2 μ M purmophamine to induce differentiation for one week.
4. The cell immunofluorescence detects the proportion of ventral nerve precursor cell marker NKX2.2 and basal plate cell marker FOXA2 positive cells in cells differentiated for 21 days to the total cells.
The results showed that the ratio of the ventral nerve precursor cell marker NKX2.2 was low in the 0.5. Mu.M pueramine group, while the ratio of NKX2.2 was high in the 2. Mu.M pueramine group and the basal plate cell marker FOXA2 remained low, and that increasing the concentration of the pueramine from 0.5. Mu.M to 2. Mu.M in the late stage of differentiation promoted ventral localization without affecting differentiation into basal plate cells
Comparative example 3
1. Hindbrain neuroepithelial cells obtained according to step 1 of example 2
2. Hindbrain ventral neural stem cells obtained according to step 2 of example 2
3. Hindbrain ventral neuronal precursor cells were obtained according to step 3 of example 2,
4. the precursor cells of step 3 in example 2 were digested and plated on glass slides, and the neuronal differentiation medium was changed directly the next day.
5. Cell immunofluorescence for 45 days of neural differentiation detects the ratio of serotonin neurons, and the result shows that the ratio of the final 5-HT positive serotonin neurons is lower than that of the serotonin neurons obtained in example 2.
During the description of the above description:
the description of the terms "this embodiment," "an embodiment of the invention," "as shown in … …," "further improved technical solution," etc., means that a particular feature, structure, material, or characteristic described in this embodiment or example is included in at least one embodiment or example of the invention; in this specification, the terminology used above is not necessarily intended to refer to the same embodiment or example, and the particular features, structures, materials, or characteristics described, etc., may be combined or coupled in any suitable manner in any one or more embodiments or examples; furthermore, those of ordinary skill in the art may combine or combine features of different embodiments or examples and features of different embodiments or examples described in this specification without undue conflict.
Finally, it should be noted that:
the above embodiments are only used for illustrating the technical solution of the present invention, and not for limiting the same;
although the present invention has been described in detail with reference to the foregoing embodiments, it should be understood by those skilled in the art that various changes and modifications may be made, and equivalents may be substituted for elements thereof without departing from the scope of the embodiments of the present invention.
Claims (10)
1. A method for differentiating caudad serotonin neurons from stem cells, comprising the steps of:
s1, culturing the pluripotent stem cells by using an E8 culture medium, wherein the fusion degree of the pluripotent stem cells reaches 60-80%, carrying out passage to a new culture plate according to 1:3, and continuously culturing by using E8;
s2, when the fusion degree of the pluripotent stem cells reaches about 80%, replacing the E8 with a first culture medium, and culturing for 6-7 days;
s3, digesting the cells by using trypLE cell digestive juice, carrying out passage to a Matrigel coated pore plate according to 1:5, replacing the cell digestive juice with a second culture medium the next day, and culturing for 6-8 days;
s4, digesting the cells by using trypLE cell digestive juice, transferring the cells to a Matrigel coated pore plate according to 1:3, changing the cell digestive juice to a third culture medium on the next day, and culturing for 6-8 days;
s5, digesting the cells by using trypLE cell digestive juice and adding 1.5-4.5 x10 4 /cm 2 Subculturing on PO-Laminin coated glass slide, changing to fourth culture medium the next day, culturing for 3-4 days, changing to neuron differentiation culture medium, and continuously culturing for 2-4 weeks to obtain mature hindbrain caudal serotonin neurons;
wherein,
the first medium comprises: nerve induction medium, SB431542, DMH1, CHIR99021;
the second medium comprises: a nerve induction medium, SB431542, DMH1, CHIR99021, purmorphamine, RA;
the third medium comprises: a nerve induction culture medium, SB431542, DMH1, CHIR99021, purmorphamine, RA and FGF4;
the fourth medium comprises: nerve induction medium, SB431542, DMH1, CHIR99021, RA and FGF4.
2. The method of differentiating caudal serotonin neurons according to claim 1, wherein said neural induction medium comprises DMEM/F12 medium, neurobasal medium, 1 xn 2,1 xb 27,1 xneaa, 1 xgutamax.
3. The method of claim 1, wherein the neuronal differentiation medium comprises Neurobasal medium, 1 xn 2,1 xb 27,1 xneaa, vitamin C, DAPT, GDNF, BDNF, TGF β 3, IGF1.
4. The method for differentiating caudad serotonin neurons from stem cells according to claim 2, wherein the volume ratio of DMEM/F12 medium to Neurobasal medium in the neural inducing medium is 1:1.
5. The method of differentiating caudal serotonin neurons from stem cells according to claim 1, wherein said second medium comprises the molar concentration (μ M) ratio between purmophamine and RA: (0.4-1): (0.1-1).
6. The method of differentiating caudal serotonin neurons from stem cells according to claim 1, wherein said third medium comprises the molar concentration (μ M) ratio between purmophamine and RA: (1-2): (0.1-1).
7. A complete set of culture medium for differentiating caudal serotonin neurons by stem cells is characterized by comprising a first culture medium, a second culture medium, a third culture medium and a fourth culture medium,
the first medium comprises: nerve induction medium, SB431542, DMH1, CHIR99021;
the second medium comprises: a nerve induction medium, SB431542, DMH1, CHIR99021, purmorphamine, RA;
the third medium comprises: a nerve induction culture medium, SB431542, DMH1, CHIR99021, purmorphamine, RA and FGF4;
the fourth medium comprises: nerve induction medium, SB431542, DMH1, CHIR99021, RA and FGF4.
8. The set of stem cell differentiation caudal serotonin neurons according to claim 7, wherein said second medium comprises purmophamine and RA in molar concentration (μ M) ratio: (0.4-1): (0.1-1).
9. The set of media of claim 7, wherein the ratio of the molar concentrations (μ M) of purmophamine and RA in the third medium is: (1-2): (0.1-1).
10. Use of caudal serotonin neurons prepared according to the method of any one of claims 1 to 6 in cell models for in vitro mechanistic studies and drug screening of diseases associated with the nervous system.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211190987.9A CN115584343A (en) | 2022-09-28 | 2022-09-28 | Method for stem cell differentiation of caudal serotonin neurons, complete culture medium and application |
PCT/CN2023/116500 WO2024066919A1 (en) | 2022-09-28 | 2023-09-01 | Method for differentiating stem cell into caudal serotonergic neuron, complete culture medium, and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211190987.9A CN115584343A (en) | 2022-09-28 | 2022-09-28 | Method for stem cell differentiation of caudal serotonin neurons, complete culture medium and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115584343A true CN115584343A (en) | 2023-01-10 |
Family
ID=84778252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211190987.9A Pending CN115584343A (en) | 2022-09-28 | 2022-09-28 | Method for stem cell differentiation of caudal serotonin neurons, complete culture medium and application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115584343A (en) |
WO (1) | WO2024066919A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024066919A1 (en) * | 2022-09-28 | 2024-04-04 | 同济大学 | Method for differentiating stem cell into caudal serotonergic neuron, complete culture medium, and use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10160950B2 (en) * | 2013-03-01 | 2018-12-25 | Wisconsin Alumni Research Foundation | Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors |
WO2015124725A1 (en) * | 2014-02-21 | 2015-08-27 | Johan Ericson | Late born central nervous system cell types |
CN104450618B (en) * | 2014-05-12 | 2015-11-04 | 南通大学 | A kind of direct directional induction mouse ES cell differentiation is fast the method for neuroepithelial cell |
CN112746057A (en) * | 2020-12-25 | 2021-05-04 | 中国人民解放军海军军医大学 | Culture system, method and application for inducing human pluripotent stem cells into neuromesodermal progenitor cells in vitro and maintaining self-renewal |
CN115584343A (en) * | 2022-09-28 | 2023-01-10 | 同济大学 | Method for stem cell differentiation of caudal serotonin neurons, complete culture medium and application |
-
2022
- 2022-09-28 CN CN202211190987.9A patent/CN115584343A/en active Pending
-
2023
- 2023-09-01 WO PCT/CN2023/116500 patent/WO2024066919A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024066919A1 (en) * | 2022-09-28 | 2024-04-04 | 同济大学 | Method for differentiating stem cell into caudal serotonergic neuron, complete culture medium, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2024066919A1 (en) | 2024-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1662645B (en) | Method for producing nerve cell | |
CN104031882B (en) | The method that human nerve stem cell directional induction in vitro is divided into dopaminergic neuron | |
CN109844102A (en) | Break up the method for pluripotent cell | |
CN1170434A (en) | In vitro Induction of dopaminergic cells | |
CN103146649A (en) | Neural stem cells | |
WO2024066919A1 (en) | Method for differentiating stem cell into caudal serotonergic neuron, complete culture medium, and use thereof | |
Tomooka et al. | Reconstruction of neural tube-like structures in vitro from primary neural precursor cells. | |
TWI438275B (en) | Method for promoting differentiation of stem cell into insulin producing cell | |
Petersen et al. | Neural stem cells derived directly from adipose tissue | |
Loffet et al. | Pluripotent stem cell derived intestinal organoids with an enteric nervous system | |
CN105838675A (en) | Hematopoietic stem cell serum-free culture medium | |
CN101124319B (en) | Neural stem cells | |
Moses et al. | Murine embryonic EGF-responsive ventral mesencephalic neurospheres display distinct regional specification and promote survival of dopaminergic neurons | |
WO2020184975A1 (en) | Spheroid culture method for neural stem cell | |
CN108486058A (en) | A method of promotion human pluripotent stem cells directed differentiation is mature neuron | |
Maxwell et al. | Midbrain dopaminergic development in vivo and in vitro from embryonic stem cells | |
CN104195102A (en) | Method for inducing human embryonic stem cells to differentiate to neuroderm | |
CN115354029B (en) | Preparation method of nerve organoid and nerve organoid | |
CN105087475A (en) | Cell culture fluid, application of cell culture fluid and method of inducting DPSCs to differentiate into neuron-like cells | |
CN107164325B (en) | The preparation method and kit of the oligodendroglia in the source MSCs | |
WO2018139600A1 (en) | Endodermal cell mass, and method for producing any one of three primary germ layer cell mass from pluripotent cells | |
US8252279B2 (en) | Methods for cell therapy | |
US7585892B2 (en) | Compound for promoting the growth of neural cells | |
CN110564673A (en) | Stem cell culture solution and application thereof | |
Noviantari et al. | Indonesian Journal of Biotechnology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |